The combination of drug regimens for immunosuppression, prevention of opportunistic infections and CFTR modulators poses a high risk for drug interactions.

Increased immunosuppression may occur. • Residual CYP3A induction by lumacaftor during transition may potentially reduce drug exposures. Oral hypoglycemics.

21 окт. 2020 г. · (Trikafta), a novel CFTR corrector/potentiator drug associated ... for immunosuppression and infection prophylaxis. FEV1/FVC 3 months ...

25 окт. 2019 г. · transplant. • Immunosuppressive drugs are required following transplantation. If Trikafta is considered, potential drug-drug interactions ...

3 июл. 2021 г. · Trikafta is the third FDA-approved drug that targets the F508del mutation of the CFTR gene. The drug is a combination of three individual drugs ...

27 мая 2022 г. · However, due to the interactions between Trikafta and immunosuppression medications, before starting Trikafta, discuss how you will monitor this ...

17 мая 2022 г. · It is authorized for people aged 12 or older weighing at least 88 pounds with mild/moderate disease who have tested positive and are “at high ...

Trikafta is used for the chronic treatment of cystic fibrosis in patients aged 6 years and older with at least one F508del mutation in the cystic fibrosis ... Не найдено: immunosuppression | Нужно включить: immunosuppression

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis.

All changes to maintenance immunosuppressive regimens were made prior to Trikafta initiation. No other CFTR modulator was ever used in any patient prior to ...